Loading...
High-sensitivity C-reactive protein, a biomarker of inflammation, independently predicts cardiovascular events. To find out whether treatment with rosuvastatin might decrease the rate of first major cardiovascular events in apparently healthy individuals, investigators for the manufacturer-sponsored Justification for the Use of Statins in Prevention: an Interventional Trial Evaluating Rosuvastatin (JUPITER) studied subjects who had high-sensitivity CRP levels ≥2 mg/L but not high cholesterol levels (LDL levels <130 mg/dL). Of 89,890 men and women who were screened for enrollment, 17,802 were randomly assigned to receive rosuvastatin (20 mg daily) or placebo. The trial was stopped after a median follow-up of 1.9 years when the data and safet…